Showing results (41-50 of 147) with videos related to
Sort By:
Pageof 15
Cancer Immunology, Immunotherapy : CII|June 30, 2019
Reduced CTL motility and activity in avascular tumor areasYoav Manaster, Zohar Shipony, Anat Hutzler, et al.Diabetes Care|February 3, 2011
Urine C-peptide creatinine ratio is a noninvasive alternative to the mixed-meal tolerance test in children and adults with type 1 diabetesRachel E J Besser, Johnny Ludvigsson, Angus G Jones, et al.Cancer Immunology, Immunotherapy : CII|May 31, 2018
Establishment of adoptive cell therapy with tumor infiltrating lymphocytes for non-small cell lung cancer patientsRonny Ben-Avi, Ronit Farhi, Alon Ben-Nun, et al.Journal of Immunology (Baltimore, Md. : 1950)|October 3, 2012
Ras oncoproteins transfer from melanoma cells to T cells and modulate their effector functionsHelly Vernitsky, Oded Rechavi, Nir Rainy, et al.Diabetes Care|January 29, 2011
Urinary C-peptide creatinine ratio is a practical outpatient tool for identifying hepatocyte nuclear factor 1-{alpha}/hepatocyte nuclear factor 4-{alpha} maturity-onset diabetes of the young from long-duration type 1 diabetesRachel E J Besser, Maggie H Shepherd, Timothy J McDonald, et al.Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|May 17, 2020
Feasibility of leukapheresis for CAR T-cell production in heavily pre-treated pediatric patientsDaphna Hutt, Bella Bielorai, Bella Baturov, et al.Bone Marrow Transplantation|February 28, 2019
Early and late hematologic toxicity following CD19 CAR-T cellsShalev Fried, Abraham Avigdor, Bella Bielorai, et al.Immunology|June 19, 2008
Dynamic expression of protective CEACAM1 on melanoma cells during specific immune attackGal Markel, Rachel Seidman, Yifat Cohen, et al.Frontiers in Oncology|October 24, 2022
Impact of cryopreservation on CAR T production and clinical responseKarin Brezinger-Dayan, Orit Itzhaki, Jenny Melnichenko, et al.Leukemia & Lymphoma|February 10, 2021
Characteristics and risk factors of infections following CD28-based CD19 CAR-T cellsTalya Wittmann Dayagi, Gilad Sherman, Bella Bielorai, et al.Pageof 15